Massachusetts-based Moderna, Inc. announced an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of the company’s mRNA vaccine candidate against the novel coronavirus.
Moderna, an MLSC Tax Incentive portfolio company, built its 200,000 square feet manufacturing plant in Norwood to advance it vast pipeline of mRNA medicines. MLSC Tax Incentives have supported job creation at a number of Massachusetts companies in the emerging field of RNA-based therapeutics.
